Biomedical scientists reports a drug — an estrogen receptor ligand called indazole chloride (IndCl) — has the potential to improve vision in patients with multiple sclerosis, or MS. The study was performed on mice induced with a model of MS and the first to investigate IndCl’s effect on the pathology and function of the complete afferent visual pathway.
Click here for original story, Remyelinating drug could improve vision in patients with multiple sclerosis
Source: ScienceDaily